Bristol Myers Squibb Company (BMY) continues to reel under pressure in 2024 as well.  The struggle does not seem to end for this biotech giant, as it has been facing a few challenges for quite some time now.The stock price of $40.75 on Jul 11 was well below its 50-day moving average of $41.67 and the 200-day moving average of $47.90. While the company is making efforts to expand its business through acquisitions to fill up the decline in revenues due to generic competition for one of the top drugs, investor ...